Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer  by Cooks, Tomer et al.
Cancer Cell
ArticleMutant p53 Prolongs NF-kB Activation
and Promotes Chronic Inflammation
and Inflammation-Associated Colorectal Cancer
Tomer Cooks,1 Ioannis S. Pateras,2 Ohad Tarcic,1 Hilla Solomon,1 Aaron J. Schetter,3 SylviaWilder,1 Guillermina Lozano,4
Eli Pikarsky,5,6 Tim Forshew,7 Nitzan Rozenfeld,7 Noam Harpaz,8 Steven Itzkowitz,9 Curtis C. Harris,3 Varda Rotter,1
Vassilis G. Gorgoulis,2,10 and Moshe Oren1,*
1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel
2Molecular Carcinogenesis Group, Department of Histology-Embryology, School of Medicine, University of Athens, 15771 Athens, Greece
3Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
4Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
5Department of Immunology and Cancer Research
6Department of Pathology
Hebrew University Hadassah Medical School, Jerusalem 91120, Israel
7Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK
8Department of Pathology
9Division of Gastroenterology, Department of Medicine
Mount Sinai School of Medicine, New York, NY 10029, USA
10Biomedical Research Foundation, Academy of Athens, 11527 Athens, Greece
*Correspondence: moshe.oren@weizmann.ac.il
http://dx.doi.org/10.1016/j.ccr.2013.03.022SUMMARYThe tumor suppressor p53 is frequently mutated in human cancer. Common mutant p53 (mutp53) isoforms
can actively promote cancer through gain-of-function (GOF) mechanisms. We report that mutp53 prolongs
TNF-a-induced NF-kB activation in cultured cells and intestinal organoid cultures. Remarkably, when
exposed to dextran sulfate sodium, mice harboring a germline p53 mutation develop severe chronic inflam-
mation and persistent tissue damage, and are highly prone to inflammation-associated colon cancer. This
mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma
with mutp53 accumulation and augmented NF-kB activation, faithfully recapitulating features frequently
observed in human colitis-associated colorectal cancer (CAC). These findingsmight explain the early appear-
ance of p53 mutations in human CAC.INTRODUCTION
The connection between inflammation and cancer has drawn
intensive research (Ben-Neriah and Karin, 2011; Demaria et al.,
2010; Hanahan and Weinberg, 2011; Schetter et al., 2010), and
has highlighted the context-dependent modulation of inflamma-
tion-associated cancer by the transcription factor NF-kB
(Ben-Neriah and Karin, 2011; He and Karin, 2011). One well-Significance
The links between chronic inflammation and cancer are the su
molecular mechanisms may be of high relevance for cance
cancer-associated mutant isoform of the p53 tumor suppress
cancer. Specifically, we report that mutant p53 acquires a sig
may promote both tumor initiation and tumor progression. Fur
features frequently seen in human colitis-associated colorecta
inflammation-associated human colorectal cancer, targeting
beneficial.
634 Cancer Cell 23, 634–646, May 13, 2013 ª2013 Elsevier Inc.documented link between chronic inflammation and human
cancer involves colorectal cancer (CRC) in patients suffering
from inflammatory bowel disease (IBD) (Asquith and Powrie,
2010; Ullman and Itzkowitz, 2011). Continuous tissue destruc-
tion and renewal, together with persistent oxidative damage
inflicted by the inflamed microenvironment, can trigger muta-
genic processes that serve as cancer-initiating events. Further
tumor progression is augmented by the continuous presencebject of extensive research. Identification of the underlying
r prevention and treatment. Here, we demonstrate that a
or promotes chronic inflammation and inflammation-driven
nificant proinflammatory activity mediated by NF-kB, which
thermore, we describe a mouse model that faithfully mimics
l cancer. As p53 mutations occur very early in the course of
those mutations in premalignant lesions may be clinically
Figure 1. Mutp53 Prolongs TNF-a-Induced
NF-kB Activation
(A) PANC-1 cells were transfected with siRNA
oligonucleotides specific for p53 (sip53) or lacZ as
control (siCon). Forty-eight hours later, TNF-awas
added at the indicated final concentrations for an
additional 24 hr. RNA was extracted and sub-
jected to qRT-PCR analysis with primers specific
for IL-8 mRNA. Values were normalized for
GAPDH mRNA in the same sample.
(B) SW480, HT29, HCT116 (+/+), and HCT116
derivatives without p53 (/) or with a knockin
p53R248W (mut) were transfected as in (A) and
exposed to 0.5 ng/ml TNF-a for 24 hr. IL-8 mRNA
was quantified as in (A).
(C) PANC-1 cells were transfected as in (A) and
exposed to 0.5 ng/ml TNF-a for the indicated
periods. RNA was extracted and subjected to
qRT-PCR analysis with primers specific for IL-8
mRNA. Values were normalized as in (A).
(D) The same RNA samples as in (B) were sub-
jected to qRT-PCR analysis with primers derived
from the first intron of the IL-8 gene. Values were
normalized as in (A).
(E) PANC-1 cells were transfected with siRNA
oligonucleotides specific for p53 (p) or scrambled
oligonucleotides as control (C), treated with
0.5 ng/ml TNF-a for the indicated time periods,
and harvested. Chromatin-bound proteins (see
Experimental Procedures) were subjected to
western blot analysis with the indicated anti-
bodies. GAPDH and H2B served to assess the
absence of cytoplasmic contamination and the
presence of chromatin, respectively. NT, non-
treated.
(F) PANC-1 cells were treated with TNF-a
(0.5 ng/ml) for 0, 0.5, or 8 hr and subjected to ChIP
with p65 and p53 antibodies, followed by qPCR
analysis with primers flanking the NF-kB site of the
IL-8 promoter or the upstream p53-responsive
element (RE) of the p21 gene (negative control).
Values are presented as percentage of input.
Error bars represent ± SD. See also Figure S1.
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Mutant p53 GOF in Inflammation and Cancerof inflammatory cytokines, which may promote excessive cell
proliferation and survival through activation of NF-kB and addi-
tional signaling pathways.
The p53 tumor suppressor provides powerful intrinsic defense
against cancer (Levine and Oren, 2009; Vousden and Prives,
2009). Mutations in the TP53 gene are the most frequent genetic
alteration in human cancer. The main selective advantage
of such mutations is through abrogation of wild-type (WT)
p53-mediated tumor suppression. Yet, at least some frequently
observed p53mutations also contribute actively to cancer devel-
opment through gain-of-function (GOF) activities (Brosh and
Rotter, 2009; Oren and Rotter, 2010; Rivlin et al., 2011). This
may involve enhancement of invasive properties, attenuation of
apoptosis, and increased genomic instability. Of note, mutant
p53 (mutp53) has been reported to augment NF-kB activation
in cultured cells presumably through direct protein-protein inter-
action (Schneider et al., 2010; Scian et al., 2005; Weisz et al.,
2007). Because NF-kB is a master regulator of inflammation
and a modulator of inflammation-associated cancer, it is plau-
sible that mutp53 GOF may also impact the latter processes.In the present study, we investigated the conjecture that
mutp53 may promote chronic inflammation and inflammation-
associated cancer.
RESULTS
Mutp53 Prolongs NF-kB Activation by TNF-a
We exploredmutp53 GOF activity employing the human pancre-
atic cancer-derived PANC-1 cell line, which harbors the
p53R273H mutant. NF-kB activation was triggered by TNF-a;
however, in addition to the usual high concentrations for short
durations, we also included longer exposures to lower concen-
trations to mimic a chronic inflammatory state. Remarkably,
siRNA-mediated transient depletion of mutp53 (Figure S1A
available online) strongly attenuated the induction of IL-8, a
prototypic NF-kB target gene, by low (0.5 ng/ml) TNF-a concen-
trations (Figure 1A, compare sip53 to siCon). This was repro-
duced with different p53 siRNA oligos and shRNA-mediated
stable mutp53 knockdown (Figure S1B), making this being an
off-target effect unlikely. Knockdown of the p65 NF-kB subunitCancer Cell 23, 634–646, May 13, 2013 ª2013 Elsevier Inc. 635
Figure 2. Mice Expressing Mutp53 Are Excessively Susceptible to
DSS
(A) Organoids composed of intestinal epithelial cells of p53+/+, p53/, and
p53m/m mice were cultured as in Experimental Procedures. Left: representa-
tive photomicrograph at both low magnification (scale bar represents 500 mm)
and higher magnification (scale bar represents 200 mm). Right: they were then
treated with TNF-a (0.5 ng/ml) for 24 hr. p53, TNF-a, and KCmRNA levels were
quantified as in Figure 1A. Bars represent ± SD.
(B) p53+/ and p53+/m mice were treated with 2% DSS at the indicated
time windows or left untreated (Con). Body weight was monitored throughout
the indicated period. Values represent average relative weight normalized
to the weight at the start of the treatment. Bars indicate standard errors.
**p < 0.01.
(C) p53+/ and p53+/m mice were treated as in (B). Mice were sacrificed at day
50 and colon lengths were measured. Distributions of individual measure-
ments along with mean and standard deviation are shown. **p < 0.01.
(D) Colons of p53+/ and p53+/m mice, either untreated (Con) or treated with
DSS, were collected at day 60 and subjected to histopathological analysis
(scale bars represent 100 mm).
See also Figure S2.
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sip65). Additional NF-kB targets were similarly affected by
mutp53 depletion (Figure S1C). Interestingly, mutp53 depen-
dence was most pronounced at low TNF-a concentrations (Fig-
ure 1A). Mutp53 depletion had no further effect in the absence of
p65 (sip53+sip65), supporting an epistatic interaction wherein
mutp53 boosts IL-8 expression via p65/NF-kB. Similar effects
of mutp53 depletion were observed in CRC-derived SW480
and HT29 cell lines (Figure 1B). Conversely, CRC-derived636 Cancer Cell 23, 634–646, May 13, 2013 ª2013 Elsevier Inc.HCT116 cells expressing only mutp53 (Figure 1B, mut) (Sur
et al., 2009) displayed elevated IL-8 induction relative to their
WT p53 (+/+) or p53 knockout (/) counterparts.
Kinetic analysis of IL-8 mRNA induction by low (0.5 ng/ml)
TNF-a revealed that mutp53 was dispensable for the rapid early
rise in IL-8 mRNA (Figure 1C). However, whereas in control
PANC-1 cells (siCon) high IL-8 mRNA persisted for many hours,
mutp53 depletion severely shortened the response duration.
Hence, mutp53 prolongs the NF-kB response to limiting
amounts of inflammatory cytokine, converting it from transient
into chronic. Consistent with earlier observations (Schneider
et al., 2010; Weisz et al., 2007), experiments employing a lucif-
erase reporter under an NF-kB-regulated promoter (Figure S1D)
confirmed a transcriptional mechanism. This was validated by
quantitative (q)RT-PCR analysis of IL-8 pre-mRNA using
intron-derived primers (Kuroda et al., 2005; Phelps et al., 2006;
Shema et al., 2008) (Figure 1D). Remarkably, this revealed a
biphasic transcriptional response, where the first rapid phase
was indifferent to mutp53, whereas the second, later phase
was highly dependent on mutp53. Thus, IL-8 transcription
reverted to basal levels by 24 hr in mutp53-depleted cells but
continued unabated in mutp53-expressing cells. Notably,
augmented association of p65 with chromatin, peaking at
30 min, remained detectable at 24 hr in mutp53-expressing (Fig-
ure 1E, C lanes) but not mutp53-depleted cells (p lanes), prob-
ably underpinning the extended transcriptional response.
Although mutp53 binds many NF-kB sites (Dell’Orso et al.,
2011), global association of mutp53 with chromatin was unal-
tered (Figure 1E). However, chromatin immunoprecipitation
(ChIP) analysis revealed recruitment of both p65 and mutp53
to the NF-kB site of the IL-8 promoter (Figure 1F). Remarkably,
mutp53 depletion resulted in complete loss of p65 occupancy
by 8 hr. Prolonged p65 retention coincided with enhanced
recruitment of mutp53; this suggests a crucial role for mutp53
in maintaining NF-kB chromatin association, consistent with
data obtained using DNA oligonucleotides (Schneider et al.,
2010). To further characterize the impact of mutp53, we per-
formed expression microarray analysis on control and mutp53-
depleted PANC-1 cells, with or without TNF-a (Gene Expression
Omnibus [GEO] accession number GSE43738). Indeed, induc-
tion of numerous genes by TNF-a was significantly attenuated
by mutp53 knockdown (Figure S1E).
To determine whether our findings apply also to nontrans-
formed epithelial cells, 3D intestinal organoid cultures (Sato
et al., 2009) (Figure 2A, left) were prepared from p53515A
‘‘knockin’’ mice carrying a germline mutp53 allele encoding
p53R172H, the mouse equivalent of the human hot spot mutant
p53R175H (Lang et al., 2004), as well as from WT (+/+) and p53
knockout (/) mice. These organoids, composed purely of
epithelial cells, were then challenged with 0.5 ng/ml TNF-a for
24 hr. Remarkably, the presence of mutp53 greatly augmented
the expression of KC (a mouse functional homolog of IL-8) and
TNF-a mRNA (Figure 2A, right), confirming the trend seen in
human cancer cells.
A similar pattern was observed when comparing mouse
embryonic fibroblasts (MEFs) of different genotypes: WT (+/+),
p53 knockout (/), and homozygous (m/m) or heterozygous
(+/m) for the p53515A allele (Figure S2A). Following exposure
to 1 or 20 ng/ml TNF-a, induction of KC mRNA was strongly
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Mutant p53 GOF in Inflammation and Cancerenhanced and prolonged in +/m and m/m MEFs. Transient p65
knockdown confirmed that this was largely NF-kB dependent
(Figure S2B). Hence, a single mutp53 allele suffices for robust
prolongation of the NF-kB response. This did not occur in
p53/MEFs, clearly demonstrating amutp53 GOF effect. Addi-
tional NF-kB-regulated cytokine genes displayed a similar trend
(Figure S2C). Likewise, primary mouse monocytes displayed a
robust mutp53-mediated increase in the amount of KC protein
secreted upon TNF-a stimulation (Figure S2D).
Thus, in both epithelial and nonepithelial cells, mutp53 en-
forces an extended NF-kB response to an otherwise self-limiting
proinflammatory trigger.
Mice Expressing Mutp53 Are Excessively Susceptible
to Chronic Inflammation and Tissue Damage
The ability ofmutp53 to establish a ‘‘chronic’’ state of NF-kBacti-
vation in cultured cells raised the question of whether mutp53
might also promote chronic inflammation and inflammation-
associated carcinogenesis in vivo. To address these possi-
bilities, p53515A mice were utilized. Of relevance, p53R175H
mutations have been detected in neoplastic and preneoplastic
lesions of colitis patients (Leedham et al., 2009; Noffsinger
et al., 2001). Repeated exposure of mice to the inflammation-
inducing agent dextran sodium sulfate (DSS) elicits a condition
resembling human IBD, including late-onset colorectal tumors
(Clapper et al., 2007). We employed DSS either in a chronic
setting, involving three intermittent cycles of DSS over a total
period of 43 days, or an acute setting, involving a single 7 day
treatment (Figure S2E; all subsequent numbering relates to
day 0).
Homozygous mutp53 mice are highly prone to early-onset
spontaneous cancer (Lang et al., 2004; Lozano, 2010; Olive
et al., 2004). Given the relatively long duration of the standard
DSS carcinogenesis protocol and the ability of a single mutp53
allele to induce a prolonged NF-kB response in primary mouse
cells (Figures S2A and S2D), we therefore opted to use heterozy-
gous mutp53 mice, whose spontaneous tumors emerge rela-
tively late (Lang et al., 2004; Olive et al., 2004). Specifically, we
compared mice carrying a single mutp53 allele (+/m) or a single
p53 knockout allele (+/).
Exposure to DSS inflicts damage to the distal colon, with
consequent weight loss. The two genotypes were similarly
affected by the first DSS cycle, exhibiting comparable weight
loss (Figure 2B). However, upon repeated DSS treatments, a
marked difference became apparent: whereas +/ mice recov-
ered fairly well, +/m mice progressively lost weight, suggesting
sustained tissue damage. Indeed, determination of colon length
at day 50 revealed more severe shortening of the colon in +/m as
compared to +/ mice (Figure 2C). Histological examination
confirmed chronic tissue damage in +/m colons, including loss
of glands, glandular architectural distortion, and extensive
edema and inflammatory infiltrates (Figure 2D), whereas +/
colons appeared to be undergoing effective tissue repair. This
was confirmed by quantitative analysis of crypt loss (Malaterre
et al., 2007) (Figure S2F). Notably, mutp53 did not significantly
affect intestinal barrier function following either acute or chronic
DSS treatment (Figure S2G). Thus, mutp53 hampers tissue
recovery and renders mice more susceptible to the deleterious
effects of DSS.The ability of mutp53 to prolong the expression of pro-
inflammatory genes, together with the exacerbated response
of +/m mice to DSS, suggested that these mice were experi-
encing accentuated chronic inflammation. This was directly
confirmed by endoscopy (Figure 3A). Unlike +/ colons, +/m
colons revealed ample evidence of active inflammation, includ-
ing diffuse mucosal erythema and edema with disappearance
of mucosal vessels and shallow ulcers. Systematic endoscopic
follow-up, applying a semiquantitative inflammatory score (see
Experimental Procedures), revealed that whereas inflammation
was similarly induced in both genotypes at early times (Fig-
ure 3B), inflammation was attenuated in +/ colons,
with most areas regaining near-normal morphology, but per-
sisted in +/m colons (Figure 3C). Hematoxylin-eosin staining
confirmed massive presence of both active and chronic con-
stituents of inflammation in +/m colons (Figure 3D), including
lymphoplasmacytic aggregates and neutrophils infiltrating the
cryptic epithelium and forming crypt abscesses (grade 5).
This was much milder in +/ colons (grade 2). Severity of
colitis was graded as described in Geboes et al. (2000), eval-
uating structural change, chronic inflammation, lamina propria
neutrophils, neutrophils in epithelium, crypt destruction, and
erosions or ulcers.
Quantification of secreted proinflammatory cytokines in the
colon (Figure 3E; Figures S3A and S3B) revealed that both geno-
types mounted an abundant cytokine response at very early
times, which subsided gradually in +/ but remained chronically
elevated in +/m mice. To assess the involvement of the colonic
epithelial cells in this response, epithelial cell-enriched (ECE)
fractions prepared from colons of both genotypes were sub-
jected to RNA analysis. Relative to +/ ECE, +/m ECE expressed
significantly higher levels of several proinflammatory cytokine
mRNAs (Figure 3F), implying augmented NF-kB activation.
Unexpectedly, p65 mRNA levels were also higher in the +/m
ECE, although p65 protein levels were not significantly elevated
(data not shown).
Thus, mice harboring a germline mutp53 allele display a mark-
edly enhanced propensity for chronic inflammation and failure to
resolve inflammation-associated tissue damage. The mice
employed here carry mutp53 in all their cells. This might augment
NF-kB activation not only in the epithelium but also in other
tissues, including the myeloid compartment, as suggested by
Figure S2D. To evaluate the relative contribution of different
tissue compartments to mutp53-driven chronic inflammation,
we generated bone marrow chimeras. Briefly, irradiated +/
and +/m mice were reconstituted with bone marrow from nonir-
radiated animals of either genotype and subjected to chronic
DSS treatment. Regardless of donor and recipient genotype,
mixed chimeras underwent substantial weight loss, albeit less
pronounced than when both donor and recipient were +/m (Fig-
ure S3C). However, good recovery was achieved when both
donor and recipient were +/. Concurrently, both types of mixed
chimera displayed elevated chronic inflammation (Figures S3D
and S3E). Hence, augmented chronic inflammation is driven by
mutp53 GOF in multiple body compartments, probably entailing
a mutually reinforcing cytokine-mediated crosstalk between the
colonic epithelium and myeloid as well as other stromal cells.
Mutp53 exerts an unequivocal GOF effect on the proinflamma-
tory transcriptional response in cultured mouse cells (FiguresCancer Cell 23, 634–646, May 13, 2013 ª2013 Elsevier Inc. 637
Figure 3. Mice Expressing Mutp53 Are
Prone to Chronic Inflammation
(A) Representative colonoscopy images of p53+/
and p53+/m mice subjected to chronic DSS treat-
ment (DSS) or left untreated (Con) at day 50.
(B andC) p53+/ and p53+/mmice, treated as in (A),
were subjected to colonoscopy at the indicated
time points and scored blindly. An average in-
flammatory score was calculated (n = 5 mice/
group). **p < 0.01.
(D) Histopathological analysis of mouse colon
sections at day 107. Low (scale bars represent
200 mm) and high (scale bars represent 50 mm)
magnifications are shown for each specimen;
dashed rectangles indicate the enlarged areas.
Asterisks indicate lymphocytic aggregations;
arrows indicate neutrophils. Note the existence of
an area with microerosion in the +/m DSS case.
(E) Colons were obtained from DSS-treated mice
at the indicated time points, and levels of secreted
TNF-a were assessed as described in Experi-
mental Procedures. Distributions of individual
mice together with mean plus standard deviation
for each group are shown. NT, nontreated.
**p < 0.01.
(F) Epithelial cell-enriched fractions were obtained
from DSS-treated mice at day 60. RNA was
extracted and subjected to qRT-PCR with primers
specific to the indicated genes. Values were
normalized to GAPDHmRNA in the same sample.
*p < 0.05; **p < 0.01.
Error bars represent ± SD. See also Figure S3.
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are not due to true GOF but rather to a dominant-negative
mechanism, wherein the p53R172H protein inactivates the
remaining WT p53 protein in the +/m mice and contributes to
chronic inflammation merely by rendering the cells practically
devoid of WT p53 activity. We therefore compared the DSS
response of homozygous p53/ and p53m/m mice. Remarkably,
weight loss in / mice was very similar to +/ and WT mice
(Figure 4A), arguing that loss ofWT p53 function does not explain
the exaggerated DSS hypersensitivity. In stark contrast, +/m
mice exhibited enhanced progressive weight loss. Although
not statistically significant, this appeared even slightly more
severe in m/m mice. The differences between / and m/m
mice were confirmed by monitoring the inflammatory score
(Figure 4B). Thus, also in vivo, mutp53 exerts proinflammatory
GOF. Indeed, DSS-treated m/m mice suffered increased
mortality (Figure 4C), presumably owing to superimposition of
persistent tissue damage on the inherent morbidity of mice
lacking WT p53.638 Cancer Cell 23, 634–646, May 13, 2013 ª2013 Elsevier Inc.Mutp53 Mice Are Highly Prone to
DSS-Induced Colon Carcinoma
The propensity of mutp53mice to perpet-
uate unresolved chronic colonic inflam-
mation raised the question of whether
they are more prone to inflammation-
associated CRC. For up to 60 days
(18 days after the last DSS cycle), no
neoplastic lesions were observed byhistopathological examination in the colons of either +/
or +/m mice (Figure 5A). However, by day 75, low-grade
dysplastic lesions were discernible in several +/m mice,
increasing in number and grade by day 90. By day 100, invasive
carcinoma was already apparent in some cases (Figure 5B).
Angular irregularly shaped glands of well-differentiated tubulo-
glandular colorectal adenocarcinoma were observed invading
through the muscularis mucosae into the submucosa. By day
120, multifocal adenocarcinoma was seen only in +/m colons,
with abundant extracellular mucin production, reminiscent of
human mucinous colorectal adenocarcinoma. The cancerous
glands penetrated the submucosa, accompanied by desmo-
plastic reaction of the surrounding stroma. The overlying
epithelium was dysplastic, encompassing areas with low- and
high-grade flat dysplasia (Figure 5C). Invasion through the mus-
cularis mucosae was confirmed by smooth muscle actin (SMA)
immunostaining (Figure 5B). Flat dysplastic lesions are hard to
detect by standard colonoscopy, particularly at early stages;
however, at later time points, suspicious dysplasia-associated
Figure 4. Gain-of-Function Effect of Mutp53
(A) Mice of the indicated genotypes were treated and analyzed as in Figure 2B.
Only DSS-treated mice are shown. Error bars represent ± SE.
(B) p53/ and p53m/m mice were treated with DSS as in Figure 2B and
monitored periodically by colonoscopy. Inflammatory scores were determined
as in Figure 3B. **p < 0.01. Error bars represent ± SD.
(C) Kaplan-Meier plot showing survival of DSS-treated p53/ and p53m/m
mice. **p < 0.01 by Mantel-Cox test.
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confirmed by gross assessment of the colon (Figure S4B) and
subsequent histopathological examination, which also revealed
the presence of invasive carcinoma with extracellular mucin pro-
duction (Figures S4C andS4D). Throughout that entire period, no
neoplastic lesions were detected in any +/ mouse. As ex-
pected, chronic inflammation was suppressed by treatment
of +/m mice with the anti-inflammatory drug sulindac, initiated
7 days after the last DSS cycle (Figures S4E and S4F). Impor-
tantly, sulindac inhibited DSS-induced carcinogenesis (Figures
S4G and S4H), confirming that this mutp53 GOF effect relies
on its ability to elicit chronic inflammation. Thus, mutp53 not
only makes the mice more susceptible to chronic inflammation
but also greatly accelerates inflammation-associated colon
cancer.
Mutp53 Accumulates in the Inflamed Colon and
in Cancerous Glands Concomitantly with NF-kB
Activation and Sustained DNA Damage
To interrogate molecular events underpinning the GOF effect of
mutp53, chromatin from mouse colons was subjected to ChIP
analysis. In colons of untreated mice, very little p65 or p53 asso-
ciated with the NF-kB site of the MIP2 gene, regardless of p53
status (Figure 6A). After a 7 day acute DSS treatment, p65 occu-
pancy increased considerably in both +/ and +/m colons.Importantly, by day 60 of chronic DSS treatment, p65 remained
markedly associated with the NF-kB site only in +/m but not +/
colons, as seen also with several additional genes (Figure S5A).
Remarkably, mutp53 was recruited to the same genomic region
upon DSS treatment, persisting through day 60. This suggests
that in the colon, like in cultured cells (Figures 1E and 1F),
mutp53 retains p65 on the chromatin for extended periods.
In colonic epithelium of untreated WT p53 mice, p53 staining
was practically undetectable by immunohistochemistry (IHC)
(Figure 6B), whereas some p53-positive nuclei were present
in +/m and m/m mice, particularly within the lower part of the
crypt. Acute 7 day DSS treatment of WT mice triggered modest
nuclear p53 accumulation in some cells (Figure 6B). Notably, this
was greatly augmented in +/m mice, and even more in m/m
ones. This p53 accumulation was likely driven by reactive
oxygen and nitrogen species (ROS and RNS) in the inflamed
microenvironment (reviewed by Schetter et al., 2010; Ullman
and Itzkowitz, 2011). Indeed, expression of inducible nitric oxide
synthase (iNOS) was most pronounced in m/m mice and least
in +/+ ones, with +/m mice exhibiting variable intermediate
iNOS levels (Figure 6C). A similar pattern, consistent with the
differential regulation of iNOS expression by WT p53 versus
mutp53 (Forrester et al., 1996), also persisted after cessation
of DSS treatment in the chronic protocol (Figure S5B). As
expected, induction of p53 in WT colons was accompanied by
upregulation of p21, a prototypical WT p53 transcriptional target
(Figures S5C andS5D, +/+). In contrast, p21was hardly detected
in p53m/m colons, confirming that the mutant p53 was transcrip-
tionally inactive.
Intense mutp53 staining persisted throughout the tumor pro-
gression sequence. It was particularly prominent in invasive
fronts of cancerous glands (Figure 6D), suggesting that in addi-
tion to cell-autonomous factors, local microenvironmental cues
may also drive persistent mutp53 stabilization. Furthermore,
the strongest mutp53 staining coincided with intense nuclear
p65 staining (Figure 6D). This implies that, like in cultured cells,
high mutp53 levels may fuel an augmented and prolonged
NF-kB response in the colonic epithelium. Interestingly, many
of those cells were also positive for phosphorylated histone
H2AX (gH2AX; Figure 6D), indicative of persistent DNA damage.
This could simply reflect the DNA damage constantly inflicted on
the cells within the chronic inflammatory microenvironment.
Alternatively, and not mutually exclusive, defective DNA repair
in the mutp53 cells might lead to gradual accumulation of unre-
paired double-strand breaks and other types of damage. Either
way, such exacerbated damage may increase genomic insta-
bility, driving the neoplastic lesions toward higher malignancy.
Mutp53 Accumulation Correlates with NF-kB Activation
in Human Colitis-Associated Cancer and Nonneoplastic
Glands
Human colitis-associated cancer (CAC) involves frequent TP53
mutations, along with abundant mutp53 protein accumulation
in the cancerous glands (reviewed in Asquith and Powrie,
2010; Ullman and Itzkowitz, 2011). To determine whether, like
in p53515A mice, this is associated with constitutive NF-kB acti-
vation, 18 formalin-fixed, paraffin-embedded CAC specimens
from two different sources were subjected to TP53 tagged-
amplicon Illumina HiSeq 2000 sequencing (Forshew et al.,Cancer Cell 23, 634–646, May 13, 2013 ª2013 Elsevier Inc. 639
Figure 5. Mutp53 Mice Are Prone to DSS-
Induced Colon Carcinoma
(A) p53+/ and p53+/m mice were treated with DSS
as in Figure 2B. Mice were sacrificed at the
indicated time points and colon sections were
subjected to histopathological analysis. Each bar
depicts the percentage of mice within a given
group scoring positive for the indicated lesions.
Numbers of animals/group are noted at the
bottom. Dys., dysplasia (low or high grade); ICa,
invasive carcinoma; NL, no lesion.
(B) Representative histopathological images of
colon sections obtained from nontreated mice
(NT) of the indicated genotypes or mice subjected
to chronic DSS treatment and sacrificed at the
indicated time points. Note the presence of low-
grade flat dysplasia in p53+/m cases at 90 days and
the development of well-differentiated carcinoma
and mucinous adenocarcinoma at days 100
and 107, respectively. Cancerous glands (white
arrowheads) invade the muscularis mucosae,
identified by SMA staining (insets). The star de-
notes a pool of extracellular mucin. Scale bars
indicate 50 mm (upper), 200 mm (middle), 600 mm
(lower), and 100 mm (insets).
(C) Low-magnification images of colon sections
from DSS-treated mice of the indicated geno-
types, obtained at day 120. Note the progressive
multifocal invasive carcinoma with prominent
mucin lakes in the p53+/m mouse. Scale bars
represent 500 mm.
See also Figure S4.
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16 tumors (Figure S6A). Based on their TP53 sequence, these tu-
mors were divided into three groups: no p53 mutations (WT p53;
2/18), missense p53 mutations (8/18), and other p53 mutations
(nonsense, frameshift, and splicing; 8/18). As expected, intense
diffuse nuclear p53 staining wasmore prominent in themissense
mutation cases (Figures 7A and 7B; Figures S6A and S6B).
Importantly, consistent with our mouse data, abundant p53
staining correlated strongly with augmented nuclear p65 staining
(Pearson correlation coefficient = 0.85), as observed also in
head-and-neck cancer and sporadic CRC (Weisz et al., 2007;
Schwitalla et al., 2013).
Intense p53 staining in tumors is generally considered indica-
tive ofmissensemutations; yet, CAC caseswith positive p53 IHC
but no detectable mutation have been reported (Yoshida et al.,
2003). Interestingly, four of our cases carried either the R213X
nonsense mutation or the chr17:7578370:C>T splice mutation,
both observed repeatedly in human tumors (http://p53.iarc.fr),
raising the intriguing possibility that suchmutations confer an un-
expected GOF. Indeed, in all those four cases, p53 staining was
considerably greater than in the remainder ‘‘other’’ mutants
(38.1 ± 13.9 average p53 % staining abundance and intensity
[%LI] versus 17.8 ± 9.7); this warrants further investigation.640 Cancer Cell 23, 634–646, May 13, 2013 ª2013 Elsevier Inc.In human CAC, mutp53 accumulation
often precedes the appearance of
detectable neoplastic lesions (Hussain
et al., 2000). To assess whether such
early mutp53 accumulation might alreadydrive constitutive NF-kB activation, IHC analysis was performed
on specimens from IBD patients experiencing chronic inflamma-
tion with no recognizable neoplastic lesions. As exemplified in
Figure 7C, the majority of glands displayed relatively weak p53
staining, with occasional areas of stronger positivity (e.g., gland
a). Typically, p21 also stained more strongly in the same areas,
arguing that the p53-positive cells were expressingWT p53, pre-
sumably activated by local stress signals. However, a few glands
(exemplified by gland b) exhibited a strikingly different pattern,
with strong diffuse nuclear p53 but practically no p21 staining;
this was retained also in more lumen-proximal sections of
the gland (Figure S6C), suggesting the presence of mutp53
throughout gland b. Remarkably, the same gland also displayed
robust NF-kB activation. Dysplasia and cancer can arise from
patches of chronically inflamed crypts containing p53 mutations
(Leedham et al., 2009); gland b might represent such a
mutp53 crypt, potentially serving as a precursor to subsequent
neoplasia. Furthermore, as in the mouse, the presence of
mutp53 within a chronically inflamed microenvironment appears
to kindle persistent NF-kB activation.
In sum, both histologically and molecularly, the p53515A DSS
mouse model of IBD-associated cancer closely reproduces
features frequently observed in its human counterpart.
Figure 6. Analysis of p53, p65, iNOS, and
gH2AX in DSS-Exposed Mice
(A) Colons of p53+/ and p53+/m mice were har-
vested without treatment (Con), immediately after
acute DSS treatment (Ac), or at day 60 of the
chronic DSS protocol (Ch), and subjected to ChIP
analysis with antibodies against mouse p65 (left)
or mouse p53 (right). Extracted DNA was sub-
jected to qPCR with primers flanking the NF-kB
site of the MIP2 gene promoter. Primers corre-
sponding to a region located far from any coding
gene (GALc) served as negative control. ChIP
values are presented as percentage of input.
**p < 0.01.
(B) Colon sections were prepared at day 7 from
mice of the indicated genotypes subjected to
acute DSS treatment, as well as from nontreated
mice (NT), and stained for p53 (scale bars repre-
sent 100 mm). Insets display a higher magnification
(scale bars in upper insets represent 50 mm and in
lower insets represent 25 mm).
(C) Colon sections prepared as in (B) were stained
with antibodies against iNOS; sections from
two +/m mice are included to show the mouse-to-
mouse variability in this genotype. Scale bars
represent 50 mm.
(D) Staining for p53, p65, and gH2AX in an invad-
ing gland within the colon of a p53+/m mouse,
collected at day 105 of the chronic DSS protocol.
Scale bars represent 50 mm.
Error bars represent ± SD. See also Figure S5.
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GOF for Accelerated Tumorigenesis
In parallel with DSS only, additional +/ and +/m mice were
exposed to a standard protocol (Tanaka et al., 2003) combining
DSS with the chemical carcinogen azoxymethane (AOM; Fig-
ure 8A). As with DSS alone, +/m mice displayed more severe
weight loss (Figure 8B). Surprisingly, tumorigenesis was not
noticeably accelerated in these mice. Instead, the entire
tumor progression pattern was altered, both genotypes rapidly
developing massive adenomatous polyps (Figures 8C and 8D)
at similar numbers and size (Figure S7A). Remarkably, regard-
less of genotype, nuclear and cytoplasmic b-catenin accumula-
tion predominated in these tumors (Figures S7B and S7C),
consistent with the frequent induction of Ctnnb mutations by
AOM (Greten et al., 2004) and indicative of robust Wnt pathway
activation. In contrast, in DSS-only tumors of +/m mice, b-cate-
nin was retained at the plasma membrane, suggesting theCancer Cell 23, 634–absence of Wnt pathway activation.
Notably, whereas Wnt pathway activa-
tion is almost unanimous in human
sporadic CRC, mostly involving early
adenomatous polyposis coli (APC) muta-
tions, such mutations are typically late
and markedly less frequent in human
CAC (Ullman and Itzkowitz, 2011). Inter-
estingly, in mice treated with AOM only,
where tumor development approximates
human sporadic CRC, the mere loss of
p53 triggers an inflammatory transcrip-tion program and promotes invasiveness (Schwitalla et al.,
2013).
Thus, inclusion of a chemical carcinogen switches the
response toward a different course with pathological andmolec-
ular features commonly observed in sporadic human CRC. In
this setting, early p53 mutations do not appear to exert much
impact.
DISCUSSION
The course of human IBD-associated neoplasia differs substan-
tially from that of spontaneous CRC. Whereas the latter is
characterized by adenomatous polyps, a few percent of which
may progress to invasive carcinoma, IBD-associated CRC often
involves flat dysplastic lesions that progress from low to high
grade and eventually may give rise to invasive carcinoma,
although tumor development may skip one of these steps646, May 13, 2013 ª2013 Elsevier Inc. 641
Figure 7. Mutp53-p65 Correlation in Human
CAC and IBD
(A) Concurrent strong immunostaining of p53
and nuclear p65 in consecutive serial sections of
a representative human CAC case carrying a
p53R273H mutation (Figure S6A, case 36102).
(B) Staining abundance and intensity were calcu-
lated for all 18 specimens as described in Fig-
ure S6A. The scatter plot depicts the p65 and p53
%LI values for each individual tumor. The Pearson
correlation coefficient for all groups together is
0.85.
(C) Immunostaining for p53, p65, and p21 in
the epithelium, within an area of severe acute
inflammation, in a human case of severe active
colitis. Upper: a low-magnification field; two
glands (a and b) are indicated by dashed rectan-
gles. Higher magnifications of gland a (middle) and
gland b (lower) are shown below. Arrows indicate
cells with intense nuclear staining. Scale bars
represent 50 mm.
See also Figure S6.
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Mutant p53 GOF in Inflammation and Cancer(Fearon, 2011; Terzic et al., 2010; Ullman and Itzkowitz, 2011).
Likewise, the underlying genetic events also differ. In sporadic
CRC, APC mutational inactivation is very often the initiating
event. In contrast, loss of APC function typically occurs late in
IBD-associated CRC, in only a minority of tumors. Conversely,
even though p53 mutations are highly abundant in both types
of CRC, they occur very early in IBD-associated CRC but are
considered late events in sporadic CRC (Brentnall et al., 1994;
Yin et al., 1993; reviewed in Fearon, 2011; Kinzler and Vogelstein,
1996; Terzic et al., 2010; Ullman and Itzkowitz, 2011). In fact, p53
mutations are enriched in inflamed colonic tissue well before
neoplastic lesions become detectable (Hussain et al., 2000).
Moreover, analysis of individual crypts suggests that p53 muta-
tions have a founder effect in driving colitis-associated carcino-
genesis (Leedham et al., 2009). Thus, p53 mutations probably
serve an initiating role in IBD-associated cancer, whereas in spo-
radic CRC they are more important for transition from localized
late adenoma to invasive carcinoma. Yet, in both scenarios,642 Cancer Cell 23, 634–646, May 13, 2013 ª2013 Elsevier Inc.onemight argue that p53mutations serve
solely to abrogate the tumor suppressor
effects of WT p53, without the need to
implicate mutp53 as having GOF.
We now show that mutp53 exerts a
distinct GOF activity through augmenting
and prolonging the response of epithelial
cells to low amounts of inflammatory
cytokine, enforcing a chronic state of
NF-kB activation. Furthermore, mutp53
instates a chronic inflammatory condition
in animals exposed to tissue damage. In
the mouse colon, this spawns invasive
carcinoma within less than 4 months.
These effects, attainable by even a single
mutp53 allele, are not reproduced by loss
of WT p53.
The greatly accelerated tumorigenesis
likely results from a combination ofenforced prolonged inflammation associated with persistent
tissue damage, increased genome instability, and augmented
capacity of mutp53-containing cells to evade apoptosis in
the face of the harsh inflammatory microenvironment. These
effects may benefit from mutp53’s ability to perpetuate NF-
kB activation through its prolonged stabilization on kB sites
associated with proinflammatory cytokine genes, probably
involving physical interactions between mutp53 and NF-kB
(Schneider et al., 2010). Notably, the course of disease in
mutp53-expressing mice bears striking resemblance to that
observed in many cases of human IBD-associated cancer,
progressing from low- to high-grade flat dysplasia and finally
to invasive carcinoma, without involvement of adenomatous
polyps. Our findings support the conjecture that the early
presence of p53 mutations in the inflamed colon of IBD
patients (Hussain et al., 2000) is not merely a reflection of
the mutagenic microenvironment but may actually be a driver
of the subsequent emergence of neoplasia by invigorating
Figure 8. Analysis of Mice Subjected to DSS+AOM
(A) Scheme of treatment schedule with DSS+AOM. p53+/ and p53+/m mice
were subjected to treatment with DSS+AOM.
(B) Weight index was monitored and calculated as in Figure 2B. **p < 0.01.
Error bars represent ± SE.
(C) p53+/ and p53+/m mice treated with DSS+AOM were periodically moni-
tored by colonoscopy. Each bar depicts the percentage of mice within a given
group bearing adenomatous polyps (AP) or no lesion (NL); the number of
animals/group is indicated at the bottom.
(D) Representative colonoscopy images of polyps in p53+/ and p53+/mmice at
day 105 of exposure to the DSS+AOM protocol.
See also Figure S7.
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harboring mutp53.
Loss of WT p53 can by itself increase DSS-induced tumori-
genesis, yielding a mixture of polypoid and flat dysplastic
lesions, some of which progress to invasive carcinoma (Chang
et al., 2007; Fujii et al., 2004). Hence, WT p53 is a relevant tumor
suppressor in this setting. Indeed, numerous studies have
revealed an intricate crosstalk between WT p53 and NF-kB,wherein WT p53 often inhibits NF-kB activation but can also
sometimes cooperate with NF-kB to orchestrate a more
vigorous stress response (Ak and Levine, 2010; Ryan et al.,
2000; Tergaonkar and Perkins, 2007; Meylan et al., 2009; Schwi-
talla et al., 2013). However, in DSS-treated p53/mice, cancer
develops with long latency (126–160 days) and partial pene-
trance, even when using high DSS (4%, compared to 2% in
our study). By contrast, we show that a single mutp53 allele
suffices to elicit a much faster and more aggressive disease
course, demonstrating a true GOF effect. Such GOF requires
the buildup of high mutp53 concentrations, typically entailing
protein stabilization (Brosh and Rotter, 2009; Oren and Rotter,
2010; Rivlin et al., 2011; Suh et al., 2011). Notably, whereas
mutp53 accumulation is usually seen in tumors but not in non-
transformed mutp53 mouse tissues (Suh et al., 2011; Terzian
et al., 2008), we find that under inflammatory conditions this
occurs already well before the onset of any observable
neoplastic events. This may be due to elevated iNOS expression
and higher ROS and RNS (Schetter et al., 2010; Ullman and
Itzkowitz, 2011), eliciting genotoxic stress with subsequent
p53 stabilization (Suh et al., 2011). A similar mechanism may
account for accumulation of mutp53 in seemingly nonneoplastic
crypts of human IBD patients, where strong p53 accumulation
in the entire crypt suggests that epithelial cells with mutp53
may have gradually taken over the crypt. Repetitive exposure
of such a crypt to oxidative stress and inflammatory cytokines,
driving constitutive NF-kB activation, probably increases its
likelihood to progress toward neoplasia.
Mutp53GOF effects are particularly prominent in the presence
of oncogenic Ras mutations, as demonstrated both in vitro and
in vivo (Acin et al., 2011; Buganim et al., 2010; Doyle et al.,
2010). Indeed,PANC-1, SW480, andHCT116cells harbormutant
K-Ras. However, similar effects are observable in HT29 cells,
which do not carry Ras mutations. Hence, although Ras muta-
tions may cooperate with mutp53, they are not obligatory for its
GOF in augmenting NF-kB activation, as reflected also by the
fact that NF-kB activation correlates with mutp53 accumulation
in CAC tumors regardless of K-Ras mutations (Figure S6).
Themice employed in this study harbor mutp53 not just in their
colonic epithelium but rather in all cell types, including adjacent
fibroblasts and mobilized inflammatory cells. Experiments
employing intestinal organoids, comprising only epithelial cells,
suggest that mutp53-driven augmentation of NF-kB activity
may suffice to drive a chronic inflammatory process. Indeed,
constitutive activation of NF-kB in the mouse intestinal epithe-
lium is sufficient to establish an inflammatory microenvironment
and promote tumorigenesis (Vlantis et al., 2011). However, non-
epithelial cells are also prone to mutp53-mediated augmented
NF-kB activation. Hence, the accelerated tumorigenesis seen
in mutp53 mice may involve a vicious cycle wherein both
epithelial and nonepithelial components engage in excessive
production of cytokines and an exaggerated response to those
cytokines, a conjecture supported by bone marrow chimera
experiments. Stromal p53 mutations have been described in
several types of human cancer, including CRC (Patocs et al.,
2007; Wernert et al., 2001), although this has subsequently
been questioned (Campbell et al., 2009). It is plausible that
a chronically inflamed microenvironment, characterized by
continuous exposure to mutagenic compounds such as ROSCancer Cell 23, 634–646, May 13, 2013 ª2013 Elsevier Inc. 643
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potentially contribute to human inflammation-associated can-
cer. In sum, our findings suggest that by augmenting NF-kB acti-
vation, the emergence of p53 mutations in a chronically inflamed
microenvironment may both exacerbate the inflammatory
response and protect the mutant cells from the deleterious
effects of this microenvironment. These GOF effects of mutp53
may account for the apparent early role of p53 mutations in
inflammation-associated carcinogenesis.EXPERIMENTAL PROCEDURES
Cell Culture, Transfection, and Infection
PANC-1 (generous gift of Yoel Kloog), SW480, HT29, and HCT116 cells and
their derivatives somatically knocked out for p53 and knocked in for the
R248W p53 mutant (Sur et al., 2009) (generous gift of Bert Vogelstein), mouse
intestinal organoids, and isolated primary mouse monocytes were maintained
at 37C in a standard 5% CO2 humidified incubator, whereas mouse embry-
onic fibroblasts obtained from C57BL/6 mice were maintained at 37C in a
5% CO2 and 3% O2 humidified incubator (Thermo Scientific). Dulbecco’s
modified Eagle’s medium (DMEM) was used for growing PANC-1, SW480,
and MEFs, McCoy’s medium for HT29 and HCT116 cells, and DMEM/F12
medium for intestinal organoids. DMEM and McCoy’s were supplemented
with 10% heat-inactivated fetal bovine serum (HI-FBS; Sigma), 2 mM L-gluta-
mine, and antibiotics. Intestinal organoids were cultured in Matrigel with
medium containing Glutamax (1003; GIBCO), B27 (1:50; Invitrogen), mouse
bFGF (10 ng/ml; Peprotech), human EGF (20 ng/ml; Peprotech), mouse noggin
(100 ng/ml; Peprotech), human r-spondin (500 ng/ml; Peprotech), and
antibiotics.
For siRNA transfections, Dharmafect 1 reagent (Dharmacon) was used ac-
cording to the manufacturer’s protocol. siRNAs for p53 and p65, as well as
control scrambled siRNA, were purchased from Dharmacon as SMARTpools.
To exclude off-target effects, ON-TARGET plus p53 siRNA oligos (Dharmacon)
were also used (sip53 II; Figure S1B).
For stable clones, ecotropic Phoenix packaging cells were transfected with
10 mg DNA of the appropriate retroviral construct by a standard calcium phos-
phate procedure. Culture supernatants were collected 36–48 hr after transfec-
tion and filtered. PANC-1 cells were infected with the filtered viral supernatants
in the presence of 4 mg/ml Polybrene (Sigma) for 12 hr, after which the medium
was changed. Fresh viral suspensions were added after a 24 hr interval for an
additional 12 hr. Infected cells were selected for 5 days in 2.5 mg/ml puromycin.
Chromatin Immunoprecipitation
Cells were crosslinked with 1% formaldehyde at room temperature for 10 min,
washed twice with 10 ml ice-cold PBS, and then scraped into 0.5 ml of
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl [pH 8.1], 1 mM PMSF,
1 mg/ml leupeptin, 1 mg/ml aprotinin) and left on ice for 10 min. Samples
were then sonicated seven times at 4C; each sonication was for 20 s, followed
by a 40 s pause. Supernatants were recovered by centrifugation at 12,000 rpm
in an Eppendorf microfuge for 10 min at 4C before being diluted 4- to 8-fold
in dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-
HCl [pH 8.1]). Samples were then precleared for 2 hr at 4C with 2 mg sheared
salmon sperm DNA and 20 ml protein A Sepharose (50% slurry). At this
stage, 50 ml of the material was kept as input. Immunoprecipitations were
performed overnight with specific antibodies (1–2 mg), with addition of
NP-40 to a final concentration of 0.5%. Immune complexes were captured
by incubation with 20 ml protein A Sepharose (50% slurry) and 2 mg salmon
sperm DNA for 1 hr at 4C. Immunoprecipitates were washed sequentially
for 5 min each at 4C in TSE 1 (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
20 mM Tris-HCl [pH 8.1], 150 mM NaCl), TSE 2 (0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.1], 500 mM NaCl), and buffer 3
(0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl
[pH 8.1]). Beads were washed twice with TE buffer (10 mM Tris-HCl, 1 mM
EDTA) and eluted with 500 ml elution buffer (1% SDS, 0.1 M NaHCO3). To
reverse the crosslinks, samples were incubated at 65C overnight, after which
DNA was eluted and subjected to qPCR. When mouse colons were subjected644 Cancer Cell 23, 634–646, May 13, 2013 ª2013 Elsevier Inc.to ChIP, epithelium was scraped as described in Guma et al. (2011) and sub-
sequently underwent the same procedure as described above. The primers
used for qPCR are listed in Supplemental Experimental Procedures.
RNA and Real-Time Quantitative PCR
RNA was isolated with a NucleoSpin RNA II kit (Macherey-Nagel). Aliquots
(1.5 mg) were reverse transcribed usingMoloney murine leukemia virus reverse
transcriptase (Promega) and random hexamer primers (Amersham). Real-time
qPCRwas performed using SYBRGreenMaster Mix (Applied Biosystems) in a
StepOnePlus instrument (Applied Biosystems). The primers used for qPCR are
listed in Supplemental Experimental Procedures.
Mice
All mouse strains were maintained on a C57BL/6 background. Cohorts were
generated by mating p53+/m or p53+/ mice. p53515A mice (Lang et al., 2004)
harbor a G-to-A substitution at nucleotide 515, resulting in an Arg-to-His sub-
stitution at amino acid position 172 of mouse p53. Genotyping was performed
by PCR analysis as described (Lang et al., 2004). Acute colitis was induced by
providing 2% dextran sodium sulfate (Millipore) for 7 days in the drinking water
of 8-week-old male mice weighing 21–25 g, whereas the chronic protocol
involved three 5 day cycles of 2% DSS separated by 14 day intervals. Mice
were monitored three times a week for overall weight, stool consistency,
and gross bleeding. Colonoscopy procedures were conducted using a
1.9 mm endoscope (Karl Storz). Mice were anesthetized with 10% xylasine
and 10% ketamine in PBS before colonoscopy. Inflammatory score assess-
ment was as described in Becker et al. (2006).
Mouseorganswere fixed in 4%formalin/PBS for 24hr, embedded inparaffin,
sectioned at 4 mm, dewaxed, and stained with hematoxylin and eosin. Proce-
dures involving animals were approved by the Animal Ethics Committee of
the Weizmann Institute (Institutional Animal Care and Use Committee number
05331109-2) and conformed to the guidelines of the Israel Council for Experi-
ments in Animals. Pathological examination was conducted blindly and inde-
pendently by two molecular pathologists advised by a mouse pathologist.
Human Tissues
Primary tumor and colon biopsies were obtained from the Cooperative Human
Tissue Network (Office of Human Subjects Research approval number 3637)
and the Mount Sinai School of Medicine. The project was approved by the
institutional review boards of the National Institutes of Health and the Mount
Sinai School of Medicine. Serially sectioned slides from formalin-fixed,
paraffin-embedded biopsies of 18 human CAC cases were obtained from
the National Cancer Institute and the Mount Sinai School of Medicine. DNA
extracted from tumor cell-enriched areas of each specimen was subjected
to TP53 tagged-amplicon Illumina HiSeq 2000 sequencing (Forshew et al.,
2012); K-Ras mutations were similarly interrogated. In parallel, additional
slides from each specimen were subjected to immunohistochemical analysis.
Microarray Hybridization and Analysis
For expression microarray analysis, RNA was extracted as described above.
RNA (10 mg) was labeled and hybridized to Affymetrix GeneChip Human
Exon 1.0 ST arrays. For analysis, the Affymetrix Expression Console (parame-
ters: annotation confidence, full; summarization method: iter-PLIER include
DABG; background: PM-GCBG; normalization method: none) was used,
followed by normalization of all arrays together using a Lowess multiarray
algorithm. Intensity-dependent estimation of noise was used for statistical
analysis of differential expression.
ACCESSION NUMBERS
The GEO accession number for the expression array data reported in this
paper is GSE43738.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2013.03.022.
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